Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease-Reference-Cited by-同舟云学术

Real-world experience with ruxolitinib therapy for steroid-refractory acute graft versus host disease

Published:2024-02-24 Issue:6 Volume:59 Page:759-764
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Murray Alistair,Linn Swe Mar,Yu Benoit,Novitzky-Basso Igor^ORCID,Mattsson Jonas,Kennah Michael,Elemary Mohamed,White Jennifer,Lemieux Christopher,Jamani Kareem,Kim Dennis Dong Hwan^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41409-024-02249-8.pdf

Reference25 articles.

1. Zeiser R, Blazar BR. Acute graft-versus-host disease — Biologic process, prevention, and therapy. N. Engl J Med. 2017;377:2167–79.

2. MacMillan ML, Robin M, Harris AC, DeFor TE, Martin PJ, Alousi A, et al. A refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality. Biol Blood Marrow Transplant. 2015;21:761–7.

3. Tarantino G, Saraceni F, Mancini G, Poiani M, Maroni L, Goteri G, et al. Gastrointestinal complications after allogeneic hematopoietic stem cell transplant: a multidisciplinary approach with early endoscopic evaluation. Clin Hematol Int. 2021;3:161.

4. Martin PJ, Rizzo JD, Wingard JR, Ballen K, Curtin PT, Cutler C, et al. First- and second-line systemic treatment of acute graft-versus-host disease: recommendations of the American Society of Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2012;18:1150–63.

5. Jamani K, Russell JA, Daly A, Stewart D, Savoie L, Duggan P, et al. Prognosis of grade 3–4 acute GVHD continues to be dismal. Bone Marrow Transpl. 2013;48:1359–61.

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New investigational drugs for steroid-refractory acute graft-versus-host disease: a review of the literature;Expert Opinion on Investigational Drugs;2024-07-09